[^1]
| Gene |
[NEFL](/genes/nfl) |
| UniProt |
P07196 |
| PDB |
1QDE, 2N3P |
| Mol. Weight |
61.5 kDa |
| Localization |
Axon, neuronal cytoplasm |
| Family |
Intermediate filament family |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers), [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth) |
Neurofilament Light Chain (NF-L), also known as NEFL, is a neuronal intermediate filament protein encoded by the NEFL gene on chromosome 8p21. NF-L is the most abundant neurofilament subunit and forms the core structural backbone of neuronal intermediate filaments in axons .
NF-L is a critical component of the neuronal cytoskeleton, providing structural support and regulating axonal caliber. It is expressed exclusively in neurons, primarily in large myelinated axons. NF-L is one of the most extensively studied biomarkers for axonal damage in neurodegenerative diseases, as it is released into cerebrospinal fluid and blood upon neuronal injury .
¶ Domain Structure
NF-L is a typical intermediate filament protein with three major domains:
¶ Head Domain (1-86)
- N-terminal non-helical domain
- Contains phosphorylation sites
- Regulates filament assembly
¶ Central Rod Domain (87-400)
- Alpha-helical coiled-coil structure
- Highly conserved across intermediate filaments
- Responsible for dimer formation
- Contains the helix start and termination motifs
¶ Tail Domain (401-543)
- C-terminal domain with variable length
- Contains phosphorylation sites (Ser/Thr)
- Projects from filament surface
- Interacts with other neurofilament subunits
- Regulates spacing between filaments
¶ Axonal Structure and Support
- NF-L forms the core structural element of neurofilaments
- Provides tensile strength to axons
- Maintains axonal diameter, which directly correlates with conduction velocity
- NF-L null mice show reduced axonal caliber and slowed nerve conduction
¶ Assembly and Polymerization
- NF-L forms heteropolymers with NF-M (NEFM) and NF-H (NEFH)
- Initial assembly as tetramers, then higher-order structures
- Phosphorylation regulates assembly state and spacing
- Proper neurofilament transport requires post-translational modifications
- Binds to plectin for cytoskeletal cross-linking
- Interacts with MAPs (Microtubule-Associated Proteins)
- Associates with voltage-gated sodium channels at nodes of Ranvier
- Links to actin microfilaments via scaffolding proteins
NF-L is one of the most validated biomarkers for neurodegeneration:
- CSF NF-L: Elevated in ALS, PD, AD, MS, and other neurodegenerative conditions
- Blood NF-L: Serum NF-L correlates with CSF levels and disease progression
- FDA-approved biomarker for ALS disease monitoring
- Predictive of conversion from prodromal to manifest disease
¶ Mutations and Disease
- NEFL mutations cause Charcot-Marie-Tooth disease type 2E (CMT2E)
- Mutations lead to neuropathy and axonal degeneration
- Some mutations disrupt neurofilament assembly
- NF-L accumulation in aggresomes seen in some neurodegenerative conditions
- Neurofilament accumulation in proximal axons is a hallmark of many neurodegenerative diseases
- Impaired axonal transport leads to neurofilament compaction
- Seen in ALS, PD, and experimental models of axonal degeneration
- NF-L fragmentation detected in vulnerable brain regions
- NF-L levels used for patient stratification and drug response monitoring
- NF-L lowering strategies being explored for neuroprotection
- Gene therapy approaches targeting NEFL expression
- NF-L used as enrollment criterion in ALS clinical trials
- Serves as pharmacodynamic biomarker for drug efficacy
- Helps identify responders vs non-responders
- Enables earlier readouts than clinical endpoints
- Antisense oligonucleotides targeting NEFL being developed
- Modulation of neurofilament phosphorylation pathways
- Small molecules to improve axonal transport
- Gene therapy for NEFL mutations in CMT2E
-
Petzold et al., Neurofilament as biomarker in neurological disorders (2023). Nature Reviews Neurology. 2023;19(4):219-234.
-
Khalil et al., Neurofilament light chain in ALS (2022). Lancet Neurology. 2022;21(11):997-1008.
-
Gaetani et al., Role of neurofilaments in neurodegenerative diseases (2019). Progress in Neurobiology. 2019;176:36-53.
-
Feneberg et al., Neurofilament light chain as biomarker in Parkinson's disease (2021). Movement Disorders. 2021;36(12):2805-2817.